Local Radiotherapy and Measurable Residual Disease-Driven Immunotherapy in Early-Stage Follicular Lymphoma (FIL MIRO) Trial: Final Results
Practical Solutions and Value Highlights:
Local radiotherapy and anti-CD20 monoclonal antibody (mAb) treatment were evaluated using a measurable residual disease (MRD)-driven approach.
Patients with early-stage follicular lymphoma were initially treated with radiotherapy, and those still MRD-positive received anti-CD20 mAb ofatumumab.
Of the patients MRD-positive after radiotherapy, 92% achieved MRD-negativity with ofatumumab, leading to a reduced incidence of relapse over time.
AI-driven platform DocSym consolidates clinical standards, protocols, and research for easy access by clinicians, streamlining operations and enhancing patient care.
Mobile apps support scheduling, treatment monitoring, and telemedicine, aiding in managing patient care and expanding digital services.
AI integration in clinics enhances workflows, improves patient outcomes, and reduces paper routines.
For more information on how we can help, visit aidevmd.com.
